Cohen JA - Search Results

1

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.

Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: cohen ja. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.

2

Clinical and subclinical neurological involvement in children of conjugal multiple sclerosis patients.

Constantinescu CS, Grossman RI, Finelli PF, Kamoun M, Zmijewski C, Cohen JA. Constantinescu CS, et al. Among authors: cohen ja. Mult Scler. 1995 Nov;1(3):170-2. doi: 10.1177/135245859500100307. Mult Scler. 1995. PMID: 9345449

3

Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis.

Marrie RA, Miller DM, Chelune GJ, Cohen JA. Marrie RA, et al. Among authors: cohen ja. Mult Scler. 2003 Dec;9(6):621-6. doi: 10.1191/1352458503ms971oa. Mult Scler. 2003. PMID: 14664477

4

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis.

Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL. Cree BA, et al. Among authors: cohen ja. Neurology. 2004 Dec 14;63(11):2039-45. doi: 10.1212/01.wnl.0000145762.60562.5d. Neurology. 2004. PMID: 15596747

5

Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis.

Marrie RA, Chelune GJ, Miller DM, Cohen JA. Marrie RA, et al. Among authors: cohen ja. Mult Scler. 2005 Feb;11(1):69-75. doi: 10.1191/1352458505ms1110oa. Mult Scler. 2005. PMID: 15732269

6

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Fox RJ, et al. Among authors: cohen ja. Mult Scler. 2005 Apr;11(2):140-5. doi: 10.1191/1352458505ms1142oa. Mult Scler. 2005. PMID: 15794385 Clinical Trial.

7

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.

Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H. Smith DR, et al. Among authors: cohen ja. Mult Scler. 2005 Oct;11(5):573-82. doi: 10.1191/1352458505ms1210oa. Mult Scler. 2005. PMID: 16193896 Clinical Trial.

8

Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.

Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M. Miller DM, et al. Among authors: cohen ja. Mult Scler. 2006 Apr;12(2):180-6. doi: 10.1191/135248506ms1270oa. Mult Scler. 2006. PMID: 16629421 Clinical Trial.

9

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Goodman AD, et al. Among authors: cohen ja, cohen r. Mult Scler. 2007 Apr;13(3):357-68. doi: 10.1177/1352458506069538. Epub 2007 Jan 29. Mult Scler. 2007. PMID: 17439905 Clinical Trial.

10

Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.

Goldman MD, Marrie RA, Cohen JA. Goldman MD, et al. Among authors: cohen ja. Mult Scler. 2008 Apr;14(3):383-90. doi: 10.1177/1352458507082607. Epub 2007 Oct 17. Mult Scler. 2008. PMID: 17942508 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

729 results

Search Page

Filters